Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
To evaluate the efficacy of olubrutinib combined with ICP-248 compared with the olubrutinib in the treatment of r/r MZL
Epistemonikos ID: 22071fbe2858639d64f0ae2a57004b3cb6c2791f
First added on: Oct 28, 2026